Zura Bio Limited (ZURA) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $511M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerZura Bio Limited (ZURA) trades at $5.38 with MoonshotScore 55/100 (Grade B). Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Price as of Sep 11, 2026 · Last analyzed: Sep 4, 2026Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Their pipeline includes ZB-168, an anti IL7R a inhibitor, and Torudokimab, a monoclonal antibody neutralizing IL33, which is in Phase 2 clinical trials.
ZURA stock analysis for 2026: Analysts have set a consensus price target of $20.00 for Zura Bio Limited, suggesting 271.7% upside from the current price of $5.38. The AI MoonshotScore is 55/100, in the Fair band (45-64) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
ZURA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Momentum (9/10, Strong). Weakest side: Growth Durability (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Zura Bio Limited Company Overview
Who Are ZURA's Competitors?
ZURA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | — |
| ZVRA Zevra Therapeutics, Inc. | $12.06 | +0.17% | $713M | — |
| PHAR Pharming Group N.V. | $10.97 | -4.61% | $776M | — |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | — |
| CLYM Climb Bio, Inc. | $14.54 | -3.42% | $832M | — |
| RIGL Rigel Pharmaceuticals, Inc. | $46.46 | -1.61% | $860M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for ZURA?
Negative return on equity (-55.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 92% of our measures
- ● Price is current
- ● No filing on record
- ● Covered by analysts
Why 55?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.58 Short-term liquidity (Financial Strength)
- +0.35 Bankruptcy-risk score (Financial Strength)
- +0.30 12-month price trend (Momentum)
What is holding it back
- -0.48 5-year net income per share (Growth)
- -0.30 Free cash flow growth (Growth)
- -0.29 Net debt vs earnings (Financial Strength)
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 53 |
| 2026-08-29 | 54 |
| 2026-09-01 | 54 |
| 2026-09-04 | 55 |
| 2026-09-07 | 57 |
| 2026-09-10 | 56 |
What changed?
The grade moved from 51 to 56 (+5).
What moved it up or down:
- +14 Valuation
- +8 Momentum
- +7 Financial Strength
Over the same 18 days the stock moved -2.4%.
Insider Activity
Over the past six months, Zura Bio Limited insiders filed 10 SEC Form 4 transactions — 0 sales and 10 purchases. On net that is roughly 1.3M shares acquired (about $7.0M) — insiders putting money in tends to read as conviction.
Forward Outlook
Wall Street analysts project Zura Bio Limited revenue of about $8.3M for fiscal 2026, with EPS near $-0.82. The estimate reflects 7 contributing analysts.
Earnings Track Record
Zura Bio Limited has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 37.0% below estimates on average.
Financial Health
Zura Bio Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 16.76 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Zura Bio Limited stands at -55.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.6%, the inverse of the P/E and a quick read on earnings relative to price.
Zura Bio Limited (ZURA) Valuation Context
Valued at $511M, ZURA is classified as a small-cap stock. Analyst price targets span from $20.00 to $20.00, with a consensus of $20.00. At the current price of $5.38, that implies approximately 272% upside potential.
ZURA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
ZURA Latest News
-
Zura Bio to Participate in the Cantor Global Healthcare Conference
businesswire.com · Aug 31, 2026
-
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
defenseworld.net · Aug 27, 2026
-
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Aug 21, 2026
-
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
benzinga · Aug 12, 2026
ZURA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ZURA.
Price Targets
Median: $20.00 (+271.7% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
ZURA MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. ZURA scores 55/100 (Grade B): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
Zura Bio to Participate in the Cantor Global Healthcare Conference
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
Latest Zura Bio Limited Analysis
Investor Questions: ZURA Stock
What does the AI Score mean for ZURA?
ZURA holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ZURA a good stock?
Stock Expert AI does not rate ZURA buy, sell or hold. Zura Bio Limited carries a MoonshotScore of 55/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for ZURA?
Zura Bio Limited (ZURA) holds an AI score of 55/100 (moderate). Analysts target $20.00 (+272%). Not financial advice.
How frequently does ZURA data refresh on this page?
ZURA's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZURA's recent stock price performance?
Zura Bio Limited (ZURA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZURA overvalued or undervalued right now?
Zura Bio Limited (ZURA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $20.00 (+272%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ZURA?
Yes, most major brokerages offer fractional shares of Zura Bio Limited (ZURA) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ZURA's earnings and financial reports?
Zura Bio Limited (ZURA) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ZURA earnings announcements.
What should investors new to ZURA understand first?
Zura Bio Limited (ZURA) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 55/100. With a market cap of $511M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.